JAK2 and hematologic disorder: The first evidence of JAK gain-of-function mutations in hematological disorders, which preceded discovery of the JAK2-V617F mutation by 10 years, was provided by the Drosophila tumorous-lethal (Tum-l) mutation in the kinase-like domain of the hopscotch locus.